2016 Innovation Competition (Boston, MA)

Developing novel therapeutics for obesity and rare metabolic disorders

Concept or business name.

Dover Lifesciences

Elevator Pitch

Dover has a genetically-validated, novel target for the treatment of obesity. We have hit molecules with nascent structural activity relationship which show inhibition in cellular and biochemical assays. Inhibition of the target protein leads to a metabolic inefficiency leading to weight loss and also provides substrate reduction therapy for a category of rare metabolic disorders

david.chung@doverlifesciences.com

Go back to "Submit an Opportunity"